VERRICA PHARMACEUTICALS INC. - COMMON STOCK

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

26 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

29 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

27 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

22 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

05 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

29 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

05 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

04 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

03 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

15 ديسمبر 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

10 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

09 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

25 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

27 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

31 أغسطس 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

24 أغسطس 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

23 أغسطس 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

10 أغسطس 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

08 أغسطس 2023 07:30:01 بحسب Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting

03 أغسطس 2023 07:30:00 بحسب Nasdaq GlobeNewswire